NCT06481943 A Prospective Research Investigation of Ischemia Using MCG
| NCT ID | NCT06481943 |
| Status | Recruiting |
| Phase | — |
| Sponsor | SB Technology, Inc. |
| Condition | Acute Coronary Syndrome |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2024-07-11 |
| Primary Completion | 2026-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2024-07-11 with a primary completion date of 2026-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
PRISM is a prospective, pilot research study that aims to systematically characterize the usefulness of CardiAQ MCG, a bedside magnetocardiography device, in the evaluation of myocardial ischemia and infarction status.
Eligibility Criteria
Inclusion Criteria: * Scheduled to undergo a diagnostic angiography or revascularization procedure for the diagnosis or treatment of ischemia or acute myocardial infarction * Ability for participant to comply with study requirements * Patient consented before the planned, clinically indicated cath-lab procedure begins to allow sufficient time for study related activities * Written informed consent Exclusion Criteria: * Present STEMI * Pregnant or breastfeeding * Having an active atrial fibrillation episode as seen on most current 12-lead ECG * Active thoracic metal implant * Poor access to follow-up
Contact & Investigator
Kit Yee Au-Yeung, PhD
STUDY DIRECTOR
SB Technology, Inc.
Frequently Asked Questions
Who can join the NCT06481943 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Coronary Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06481943 currently recruiting?
Yes, NCT06481943 is actively recruiting participants. Contact the research team at clinical-trials@sandboxquantum.com for enrollment information.
Where is the NCT06481943 trial being conducted?
This trial is being conducted at Rochester, United States, New York, United States.
Who is sponsoring the NCT06481943 clinical trial?
NCT06481943 is sponsored by SB Technology, Inc.. The principal investigator is Kit Yee Au-Yeung, PhD at SB Technology, Inc.. The trial plans to enroll 150 participants.